SEARCH

SEARCH BY CITATION

References

  • 1
    Salem L, Devlin A, Sullivan SD, Flum DR. A cost-effectiveness analysis of laparoscopic gastric bypass, adjustable gastric banding and non-surgical weight loss interventions. Surg Obes Relat Dis 2008; 4: 2632.
  • 2
    Mokdad A, Serdula M, Dietz W, Bowman B, Marks J, Koplan J. The continuing epidemic of obesity in the United States. JAMA 2000; 284: 16501651.
  • 3
    Hollenbeak CS, Rogers AM, Barrus B, Wadiwala I, Cooney RN. Surgical volume impacts bariatric surgery mortality: a case for centers of excellence. Surgery 2008; 144: 736743.
  • 4
    Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab 2008; 93 (11 Suppl. 1): S89S96.
  • 5
    Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 15231529.
  • 6
    World Health Organization. World Health Report. 2002. [WWW document]. URL http://www.who.int/whr/2002/en/whr02_en.pdf(accessed July 2010).
  • 7
    Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA 2003; 289: 187193.
  • 8
    Waseem T, Mogensen KM, Lautz DB, Robinson MK. Pathophysiology of obesity: why surgery remains the most effective treatment. Obes Surg 2007; 17: 13891398.
  • 9
    Woodard GA, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton JM. One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg 2010; 20: 578582.
  • 10
    McTigue KM, Harris R, Hemphill B, Lux L, Sutton S, Bunton AJ, Lohr KN. Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003; 139: 933949.
  • 11
    Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 17241737.
  • 12
    Marsk R, Freedman J, Tynelius P, Rasmussen F, Näslund E. Antiobesity surgery in Sweden from 1980 to 2005: a population-based study with a focus on mortality. Ann Surg 2008; 248: 777781.
  • 13
    Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753761.
  • 14
    Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM, Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741752.
  • 15
    Sjöström L, Gummesson A, Sjöström CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Carlsson LM, Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009; 10: 653662.
  • 16
    Christou NV, Sampalis JS, Liberman M, Look D, Auger S, McLean AP, MacLean LD. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240: 416423.
  • 17
    Korner J, Inabnet W, Febres G, Conwell IM, McMahon DJ, Salas R, Taveras C, Schrope B, Bessler M. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 2009; 33: 786795.
  • 18
    Gagner M, Milone L, Trelles N. Mortality after laparoscopic adjustable gastric banding: results from an anonymous questionnaire to ASBS members. Obes Surg 2009; 19: 16571663.
  • 19
    Tice JA, Karliner L, Walsh J, Petersen AJ, Feldman MD. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med 2008; 121: 885893.
  • 20
    Angrisani L, Lorenzo M, Borrelli V. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surg Obes Relat Dis 2007; 3: 127132.
  • 21
    Crémieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M. The impact of bariatric surgery on comorbidities and medication use among obese patients. Obes Surg 2010; 20: 861870.
  • 22
    Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 26832693.
  • 23
    Sjöström L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, Hallgren P, Jonsson E, Karlsson J, Lapidus L. Swedish Obese Subjects (SOS): recruitment for an intervention study and a selected description of the obese state. Int J Obes Relat Metab Disord 1992; 16: 465479.
  • 24
    Frachetti KJ, Goldfine AB. Bariatric surgery for diabetes management. Curr Opin Endocrinol Diabetes Obes 2009; 16: 119124.
  • 25
    Renard E. Bariatric surgery in patients with late-stage type 2 diabetes: expected beneficial effects on risk ratio and outcomes. Diabetes Metab 2009; 35: 564568.
  • 26
    Levy P, Fried M, Santini F, Finer N. The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg 2007; 17: 12481256.
  • 27
    Shah SS, Todkar JS, Shah PS, Cummings DE. Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index <35 kg/m(2). Surg Obes Relat Dis 2010; 6: 332338. Sep 3. [Epub ahead of print].
  • 28
    Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Preventing macrovascular complications of diabetes: where do we stand with glycemic control? Expert Opin Investig Drugs 2008; 17: 17771779.
  • 29
    Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective? Curr Vasc Pharmacol 2010; 8: 14.
  • 30
    Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother 2010; 11: 723730.
  • 31
    Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes – a systematic review. Diabetes Metab Res Rev 2004; 20: 438445.
  • 32
    Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248256.
  • 33
    Hinojosa MW, Varela JE, Smith BR, Che F, Nguyen NT. Resolution of systemic hypertension after laparoscopic gastric bypass. J Gastrointest Surg 2009; 13: 793797.
  • 34
    Chowbey PK, Dhawan K, Khullar R, Sharma A, Soni V, Baijal M, Mittal T. Laparoscopic sleeve gastrectomy: an Indian experience-surgical technique and early results. Obes Surg 2010; 20: 13401347. Sep 29. [Epub ahead of print].
  • 35
    Dunkle-Blatter SE, St Jean MR, Whitehead C, Strodel W 3rd, Bennotti PN, Still C, Reed MJ, Wood CG, Petrick AT. Outcomes among elderly bariatric patients at a high-volume center. Surg Obes Relat Dis 2007; 3: 163169.
  • 36
    Pajecki D, Dalcanalle L, Souza de Oliveira CP, Zilberstein B, Halpern A, Garrido AB Jr, Cecconello I. Follow-up of Roux-en-Y gastric bypass patients at 5 or more years postoperatively. Obes Surg 2007; 17: 601607.
  • 37
    Carlin AM, Yager KM, Rao DS. Vitamin D depletion impairs hypertension resolution after Roux-en-Y gastric bypass. Am J Surg 2008; 195: 349352.
  • 38
    Carlin AM, Rao DS, Yager KM, Parikh NJ, Kapke A. Treatment of vitamin D depletion after Roux-en-Y gastric bypass: a randomized prospective clinical trial. Surg Obes Relat Dis 2009; 5: 444449.
  • 39
    Anagnostis P, Athyros VG, Adamidou F, Florentin M, Karagiannis A. Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? Curr Vasc Pharmacol 2010; 8: 720730. Feb 25. [Epub ahead of print].
  • 40
    Nguyen NT, Varela E, Sabio A, Tran CL, Stamos M, Wilson SE. Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J Am Coll Surg 2006; 203: 2429.
  • 41
    Dixon JB, O'Brien PE. Lipid profile in the severely obese: changes with weight loss after Lap-Band surgery. Obes Res 2002; 10: 903910.
  • 42
    Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomized trials of statins. Lancet 2005; 366: 12671278.
  • 43
    Segal JB, Clark JM, Shore AD, Dominici F, Magnuson T, Richards TM, Weiner JP, Bass EB, Wu AW, Makary MA. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg 2009; 19: 16461656.
  • 44
    Tziomalos K, Athyros VG, Karagiannis A, Kolovou GD, Mikhailidis DP. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets 2009; 10: 320327.
  • 45
    Athyros VG, Kakafika AI, Wierzbicki AS, Karagiannis A, Mikhailidis DP. Targeting triglycerides in secondary prevention: should we bother? Int J Clin Pract 2009; 63: 1518.
  • 46
    Athyros VG, Kakafika AI, Papageorgiou A, Tziomalos K, Skaperdas A, Pagourelias E, Pirpasopoulou A, Karagiannis A, Mikhailidis DP, GREACE Study Collaborative Group. Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids 2007; 42: 9991009.
  • 47
    Athyros VG, Mikhailidis DP, Kakafika AI, Karagiannis A, Hatzitolios A, Tziomalos K, Ganotakis E, Liberopoulos E, Elisaf M. Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets 2007; 8: 483488.
  • 48
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 27352752.
  • 49
    Athyros VG, Ganotakis ES, Elisaf MS, Liberopoulos EN, Goudevenos IA, Karagiannis A, GREECE-METS Collaborative Group. Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol 2007; 117: 204210.
  • 50
    Ocón Bretón J, García B, Benito P, Gimeno S, García R, López P. Effect of gastric bypass on the metabolic syndrome and on cardiovascular risk. Nutr Hosp 2010; 25: 6771.
  • 51
    Ali MR, Fuller WD, Rasmussen J. Detailed description of early response of metabolic syndrome after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2009; 5: 346351.
  • 52
    Batsis JA, Romero-Corral A, Collazo-Clavell M, Sarr MG, Somers VK, Lopez-Jimenez F. The effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc 2008; 83: 897907.
  • 53
    Athyros VG, Ganotakis ES, Bathianaki M, Monedas I, Goudevenos IA, Papageorgiou AA, Papathanasiou A, Kakafika AI, Mikhailidis DP, Elisaf M, MetS-Greece Collaborative Group. Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol 2005; 46: 380386.
  • 54
    Athyros VG, Elisaf M, Mikhailidis DP. Inflammatory markers and the metabolic syndrome. Atherosclerosis 2005; 183: 187188.
  • 55
    Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 112.
  • 56
    Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009; 15: 479489.
  • 57
    Athyros VG, Tziomalos K, Karagiannis A, Anagnostis P, Mikhailidis DP. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets 2010; 11: 122135.
  • 58
    Chen SB, Lee YC, Ser KH, Chen JC, Chen SC, Hsieh HF, Lee WJ. Serum C-reactive protein and white blood cell count in morbidly obese surgical patients. Obes Surg 2009; 19: 461466.
  • 59
    Athyros VG, Mikhailidis DP, Papageorgiou A, Didangelos T, Peletidou A, Kleta D, Karagiannis A, Kakafika AI, Tziomalos K, Elisaf M. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005; 54: 10651074.
  • 60
    Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007; 47: 642652.
  • 61
    Tziomalos K, Dimitroula HV, Katsiki N, Savopoulos C, Hatzitolios AI. Effects of lifestyle measures, antiobesity agents and bariatric surgery on serological markers of inflammation in obese patients. Mediators Inflamm 2010; 2010: 364957.
  • 62
    Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, Eid GM, Ramanathan R, Taylor DS, Schauer PR. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242: 610617.
  • 63
    Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595602.
  • 64
    Liberopoulos EN, Athyros VG, Elisaf MS, Mikhailidis DP. Statins for non-alcoholic fatty liver disease: a new indication? Aliment Pharmacol Ther 2006; 24: 698699.
  • 65
    Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873883.
  • 66
    Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006; 101: 368373.
    Direct Link:
  • 67
    Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 2007; 17: 486492.
  • 68
    Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005; 13: 11801186.
  • 69
    de Almeida SR, Rocha PR, Sanches MD, Leite VH, da Silva RA, Diniz MT, Diniz Mde F, Rocha AL. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006; 16: 270278.
  • 70
    Navarro-Díaz M, Serra A, Romero R, Bonet J, Bayés B, Homs M, Pérez N, Bonal J. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006; 17 (12 Suppl. 3): S213S217.
  • 71
    Praga M. Obesity: a neglected culprit in renal disease. Nephrol Dial Transplant 2002; 17: 11571159.
  • 72
    Dengel DR, Goldberg AP, Mayuga RS, Kairis GM, Weir MR. Insulin resistance, elevated glomerular filtration fraction and renal injury. Hypertension 1996; 28: 127132.
  • 73
    Wolf G, Hamann A, Han DC, Thaiss F, Ziyadeh FN, Stahl RA. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells. Potential role in glomerulosclerosis. Kidney Int 1999; 56: 860872.
  • 74
    Wolf G. After all those fat years: renal consequences of obesity. Nephrol Dial Transplant 2003; 18: 24712474.
  • 75
    Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Díaz-González R, Rodicio JL. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 21112118.
  • 76
    Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezène F, Berthoux F. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720727.
  • 77
    Praga M, Hernandez E, Andres A, Leon M, Ruilope LM, Rodicio JL. Effects of body weight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995; 70: 3541.
  • 78
    Serpa Neto A, Bianco Rossi FM, Dal Moro Amarante R, Alves Buriti N, Cunha Barbosa Saheb G, Rossi M. Effect of weight loss after Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obese patients. J Nephrol 2009; 22: 637646.
  • 79
    Navaneethan SD, Kelly KR, Sabbagh F, Schauer PR, Kirwan JP, Kashyap SR. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg 2010; 20: 308315.
  • 80
    Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005; 23: S27S33.
  • 81
    Algahim MF, Lux TR, Leichman JG, Boyer AF, Miller CC 3rd, Laing ST, Wilson EB, Scarborough T, Yu S, Snyder B, Wolin-Riklin C, Kyle UG, Taegtmeyer H. Progressive regression of left ventricular hypertrophy two years after bariatric surgery. Am J Med 2010; 123: 549555.
  • 82
    Garza CA, Pellikka PA, Somers VK, Sarr MG, Collazo-Clavell ML, Korenfeld Y, Lopez-Jimenez F. Structural and functional changes in left and right ventricles after major weight loss following bariatric surgery for morbid obesity. Am J Cardiol 2010; 105: 550556.
  • 83
    Jhaveri RR, Pond KK, Hauser TH, Kissinger KV, Goepfert L, Schneider B, Jones DB, Manning WJ. Cardiac remodeling after substantial weight loss: a prospective cardiac magnetic resonance study after bariatric surgery. Surg Obes Relat Dis 2009; 5: 648652.
  • 84
    Alam I, Lewis MJ, Lewis KE, Stephens JW, Baxter JN. Influence of bariatric surgery on indices of cardiac autonomic control. Auton Neurosci 2009; 151: 168173.
  • 85
    Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 19061914.
  • 86
    Fritscher LG, Mottin CC, Canani S, Chatkin JM. Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obes Surg 2007; 17: 9599.
  • 87
    Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest 2010; 137: 711719.
  • 88
    Leinum CJ, Dopp JM, Morgan BJ. Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment. Nutr Clin Pract 2009; 24: 675687.
  • 89
    Rasheid S, Banasiak M, Gallagher SF, Lipska A, Kaba S, Ventimiglia D, Anderson WM, Murr MM. Gastric bypass is an effective treatment for obstructive sleep apnea in patients with clinically significant obesity. Obes Surg 2003; 13: 5861.
  • 90
    Habib P, Scrocco JD, Terek M, Vanek V, Mikolich JR. Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol 2009; 104: 12511255.
  • 91
    Sledzinski T, Sledzinski M, Smolenski RT, Swierczynski J. Increased serum nitric oxide concentration after bariatric surgery – a potential mechanism for cardiovascular benefit. Obes Surg 2010; 20: 204210.
  • 92
    Ay L, Kopp HP, Brix JM, Ay C, Quehenberger P, Schernthaner GH, Pabinger I, Schernthaner G. Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost 2010; 8: 759765.
  • 93
    Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP. Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010; 8: 1228.
  • 94
    Batsis JA, Lopez-Jimenez F, Collazo-Clavell ML, Clark MM, Somers VK, Sarr MG. Quality of life after bariatric surgery: a population-based cohort study. Am J Med 2009; 122: 10551010.
  • 95
    Vogel JA, Franklin BA, Zalesin KC, Trivax JE, Krause KR, Chengelis DL, McCullough PA. Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery. Am J Cardiol 2007; 99: 222226.
  • 96
    Batsis JA, Sarr MG, Collazo-Clavell ML, Thomas RJ, Romero-Corral A, Somers VK, Lopez-Jimenez F. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol 2008; 102: 930937.
  • 97
    Torquati A, Wright K, Melvin W, Richards W. Effect of gastric bypass operation on Framingham and actual risk of cardiovascular events in class II to III obesity. J Am Coll Surg 2007; 204: 776782.
  • 98
    Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142: 621632.